Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Immunotherapy using peptides has been successful for some patients with allergies, but has not yet been deployed in autoimmune diseases, which may involve greater safety risks. Alhadj Ali et al. designed a placebo-controlled trial to determine whether a proinsulin peptide could safely elicit immune and metabolic responses in people recently diagnosed with type 1 diabetes without accelerating disease.
Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development? Christine Therese Ferrara, Susan Michelle Geyer, Yuk-Fun Liu, Carmella Evans-Molina, Ingrid M. Libman, Rachel Besser, Dorothy J. Becker, Henry Rodriguez, Antoinette Moran, Stephen E. Gitelman, Maria J. Redondo, the Type 1 Diabetes TrialNet Study Group Diabetes Care May 2017, 40 (5) 698-701; DOI: 10.2337/dc16-2331
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
